BioNTech, Fosun start Phase II trial of COVID-19 vaccine in China - Telenor

Breaking

By PanTech

test banner

Post Top Ad

Responsive Ads Here

Post Top Ad

Responsive Ads Here

November 26, 2020

BioNTech, Fosun start Phase II trial of COVID-19 vaccine in China


(Reuters) BioNTech and Shanghai Fosun Pharmaceutical said on Wednesday they would launch a Phase II clinical trial of BioNTech’s experimental COVID-19 vaccine in China.


The vaccine, known as BNT162b2, will be tested on volunteers at the Jiangsu Provincial Center for Disease Control and Prevention to assess safety and immunogenicity, eyeing future approval in China, the two companies said in a statement.


BioNTech is also working with U.S. pharma giant Pfizer on the vaccine and the partners said last week they were hoping to win approval in the United States and Europe this year after trial results showed the compound had a 95% efficacy rate and caused no serious side effects.


Source: Reuters; Reporting by Ludwig Burger; editing by Thomas Seythal

No comments:

Post a Comment

Post Top Ad

Responsive Ads Here